Get started
Work

Assessment of readability of gynecologic cancer clinical trials literature at National Cancer Institute–designated Comprehensive Cancer Centers

Year: 2025
Type: article
DOI: 10.1016/j.ijgc.2025.101693
Authors: Julia Chalif, Wafa Khadraoui, John L. Hays, Larry J. Copeland, Roberto Vargas, David M. O’Malley, Laura M. Chambers
Language: English
Open Access status: bronze
Funders: Doris Duke Charitable Foundation, John Templeton Foundation, Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Yale University, Ohio State University, Array BioPharma, Center for Clinical and Translational Science, University of Illinois at Chicago, Ludwig Institute for Cancer Research, Regeneron Pharmaceuticals, Novocure, Ovarian Cancer Research Fund Alliance, Pelotonia, Mersana Therapeutics, Myriad Genetics, BeiGene, Seagen, Eisai, National Institutes of Health, Genentech, EMD Serono, College of Medicine Office of Research, Ohio State University, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences, Clinical and Translational Science Center, Weill Cornell Medical College
Awards: The Ohio State University Center for clinical and Translational Science, G6422546049, G7820408181, COVID-19 Fund to Retain Clinical Scientists, OSU K12 Training Grant in Oncology, Advanced research training in immunology for surgery trainees (ARTIST)
OpenAlex ID: W4407260471
FWCI: 1.252
Cites: 32
Cited by: 1
Related to: 10